

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/581,511	10/06/2000	Raymond Andersen	P108281-0000	6795
7:	590 02/20/2002			
Arent Fox Kintner Plotkin & Kahn Suite 600 1050 Connecticut Avenue NW			EXAMINER	
			LUKTON, DAVID	
Washington, DC 20036-5339			ART UNIT	PAPER NUMBER
			1653	
			DATE MAIL ED: 02/20/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/581,511

Applicant(s)

Examiner

David Lukton

Art Unit 1653

Andersen

Th MAILING DATE of this communication appears	on th cover sh et with the correspondence address	
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SE THE MAILING DATE OF THIS COMMUNICATION.	T TO EXPIRE MONTH(S) FROM	
 Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a rep 		
 be considered timely. If NO period for reply is specified above, the maximum statutory period communication. 	will apply and will expire SIX (6) MONTHS from the mailing date of this	
 Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). 	e, cause the application to become ABANDONED (35 U.S.C. § 133). g date of this communication, even if timely filed, may reduce any	
Status	•	
1) 🕅 Responsive to communication(s) filed on <u>Jan 18, 2</u> 0	002	
2a) ☐ This action is FINAL . 2b) ☒ This acti	on is non-final.	
3) Since this application is in condition for allowance exclosed in accordance with the practice under Ex pa		
Disposition of Claims		
•	is/are pending in the applica	
4a) Of the above, claim(s) <u>19-21</u>	is/are withdrawn from considera	
5)	is/are allowed.	
6)	is/are rejected.	
7)	is/are objected to.	
8) 🕅 Claims <u>1-18</u>	are subject to restriction and/or election requirem	
Application Papers		
9) The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/a	re objected to by the Examiner.	
11) The proposed drawing correction filed on	is: a ☐ approved b) ☐ disapproved.	
12) The oath or declaration is objected to by the Examine	er.	
Priority under 35 U.S.C. § 119	riturundar 25 I.I.S. C. S. 110/a) (d)	
13) ☐ Acknowledgement is made of a claim for foreign prio a) ☐ All b) ☐ Some* c) ☐None of:	inty under 33 0.3.0. § 119(a)-(u).	
Certified copies of the priority documents have limited to the priority documents have limi	been received.	
<u> </u>	been received in Application No	
3. Copies of the certified copies of the priority doci	(PCT Rule 17.2(a)).	
*See the attached detailed Office action for a list of the c 14) \(\subseteq Acknowledgement is made of a claim for domestic pr		
Acknowledgement is made of a claim for domestic pr	ionty under 35 0.5.C. § 119(e).	
Attachment(s)		
15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).	
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)	
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:	

Applicants' election of Group I with traverse is acknowledged. Claims 19-21 are withdrawn from consideration. Upon reconsideration, the restriction is revised. First, however, the following subgenera are defined:

- G1: variable "Y" is C_1 - C_6 unsaturated alkyl; the unsaturated alkyl group is optionally substituted as the claims permit;
- G2: variable "Z" is any of the following: OH, OR, SH, SR, NH₂, NHCH(R₁₁)-COOH or NRCH(R₁₁)-COOH;
- G3: variable "Y" is C_1 - C_6 saturated alkyl; the saturated alkyl group is optionally substituted as the claims permit;
- G4: variable "Z" can be whatever the claims permit, provided that G2 is excluded;
- G5: "R" is a "skeleton" which contains "zero" nitrogen atoms, but may be substituted as the claims permit;
- G6: "R" is a "skeleton" which contains at least one nitrogen atom, and may be substituted as the claims permit

Restriction to one of the following inventions is required under 35 U.S.C. §121 (the numbering starts with Roman numeral "V", to avoid any redundancy):

- V. Claims 1-18, drawn to compounds, limited to G1 and G2.
- VI. Claims 1-7, 11-17, drawn to compounds, limited to G1 and G4.
- VII. Claims 1-9, 11-17, drawn to compounds, limited to G2 and G3; substituent variable "R" can vary as the claims permit.

VIII. Claims 1-7, 11-17, drawn to compounds, limited to G3, G4 and G5.

IX. Claims 1-7, 11-17, drawn to compounds, limited to G3, G4 and G6.

The claimed inventions are distinct. The structures differ, and one can expect the physical and biological properties to differ. Notwithstanding the foregoing, in the event that claims are found allowable, the corresponding method-of-making claim will be rejoined for further examination.

*

Applicants have argued that they enjoy "immunity" from restriction, because they have previously filed a PCT application. However, applicants are not correct. Consider the following passage (MPEP 1850)

PCT Rule 13.2, as it was modified effective 01 July 1992, no longer specifies the combinations of categories of invention which are considered to have unity of invention. Those categories, which now appear as a part of Annex B to the Administrative Instructions, has been substituted with a statement describing the method for determining whether the requirement of unity of invention is satisfied.

Unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more special technical features. The term "special technical features" is defined as meaning those technical features that define a contribution which each of the inventions considered as a whole, makes over the prior art.

The determination is made based on the contents of the claims as interpreted in light of the description and drawings. Annex B also contains examples concerning unity of invention.

Independent and Dependent Claims.

Unity of invention has to be considered in the first place only in relation to the independent claims in an international application and not the dependent claims. By "dependent" claim is meant a claim which contains all the features of another claim and is in the same category

of claim as that other claim (the expression "category of claim" referring to the classification of claims according to the subject matter of the invention claimed for example, product, process, use or apparatus or means, etc.).

If the independent claims avoid the prior art and satisfy the requirement of unity of invention, no problem of lack of unity arises in respect of any claims that depend on the independent claims. In particular, it does not matter if a dependent claim itself contains a further invention. Equally, no problem arises in the case of a genus/species situation where the genus claim avoids the prior art. Moreover, no problem arises in the case of a combination/subcombination where the subcombination claim avoids the prior art and the combination claim includes all the features of the subcombination.

If, however, an independent claim does not avoid the prior art, then the question whether there is still an inventive link between all the claims dependent on that claim needs to be carefully considered. If there is <u>no link remaining</u>, an objection of <u>lack of unity</u> (that is, arising only after assessment of the prior art) may be raised. Similar considerations apply in the case of a genus/species or combination/subcombination situation.

As it happens, the claimed genus encompasses many known peptides, and peptidomimetic compounds. Undoubtedly, there are many novel compounds with the genus, particularly within Group V. In the event that a valid §102 or §103 rejection is applied against the genus as a whole, the question of multiple inventions versus one invention can again be revisited. If there is just one invention, then the §102 or §103 rejection would be applicable against all embodiments. Alternatively, if there are in fact multiple inventions, then the reference would <u>not</u> be applicable against all embodiments.

Consider the case where variable "R1" is "R". As it happens, variable "R" includes peptides. To illustrate, suppose one began with the following simple branched alkane: 2, 4, 6-trimethyl heptane. This can be represented as follows:

Me-CH(Me)CH2-CH(Me)-CH2-CH(Me)CH3

If one were to then introduce two nitrogen atoms, and to substitute with -NH₂, one would obtain the following:

CH₃-CH(H₂N)(Me)CH₂-NH-CH(Me)-CH₂-NH-CH(Me)CH₃

If one were to then substitute three of the carbon atoms with oxo, one would obtain the following:

CH3-CH(H₂N)(Me)CO-NH-CH(Me)-CO-NH-CH(Me)CO-

The resulting moiety is the tripeptide Ala-Ala. At this point, any of the side chains of the alanines could be "substituted" with a group such as carboxyl, hydroxyl or -SH.

Similarly, at the C-terminal end of the structure of formula I variable, R_9 is present. Suppose that variable "Y" represents methylene. Then variable R_9 is the following:

-CH₂-CO-NHR

Again, variable "R" can be a peptide; in addition, variable "Y" is not confined to methylene; it could represent, for example, the amino acid valine (minus the amino and carboxyl groups) or it could represent serine (minus the amino and carboxyl groups), etc.

Applicant is advised that for the response to this requirement to be complete, an election of the invention to be examined must be indicated, even if the requirement is traversed (37 C.F.R. 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

Presumably, applicants will elect Group V. However, in the event that applicants elect a group other than Group V, a new species election will be required.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are witten in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton. Phone: (703) 308-3213.

An inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

DAVID LURTON PATENT EXAMINER GROUP 1800